BPC Instruments is a global Swedish-based technology company developing and offering analytical instruments enabling more efficient, reliable, and high quality of research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also significant reduction in time consumption and labour requirement for performing analyses. With deep knowledge and experience in target applications, BPC Instruments offers innovative products that feature high-quality hardware and software.The solutions are the first of their kind, making the company a pioneer in its field. Today, BPC Instruments exports to nearly 70 countries around the world.
BPC Instruments’ shares are listed on Spotlight Stock Market since December 16, 2021. The shares are traded under the ticker name “BPCINS”, with ISIN code SE0017130826.
1. Proven track record
BPC Instruments boasts an impressive business record, serving as a solid foundation for future growth. The company’s history of successful operations and achievements demonstrates its ability to capitalize on new opportunities and navigate challenges effectively.
BPC Instruments has evolved from being a niche player in a single market to establishing a niche presence across multiple biotechnology sectors. This diversification strategy not only mitigates risks but also opens up new growth opportunities.
3. Focus on green technologies
With a core focus on green technologies, renewable resources, sustainability, and innovation in biotechnology analysis, BPC Instruments aligns itself with the growing global demand for environmentally responsible solutions. This strategic positioning contributes to long-term sustainability and market relevance.
4. Digital transformation
The company is swiftly embracing digitalization in marketing, sales, product training, and support. This proactive approach ensures that BPC Instruments remains competitive in the rapidly evolving tech-driven landscape, enhancing customer engagement and operational efficiency.
5. Team of experts
BPC Instruments is backed by a highly competent staff known for their excellent teamwork and passion for the company’s mission. The management team and board bring a wealth of business and scientific expertise to the table, ensuring strategic direction and decision-making that drives sustainable growth.
Biotech laboratory analyses can be incredibly time-consuming and labor-intensive. BPC’s smart analytical instruments reduce the need for manual labor, streamlining traditional biotech lab processes.
Manual operations often introduce random errors into the process. BPC’s intelligent analytical instruments help biotech labs minimize these errors, ensuring consistently accurate data.
Manual methods often yield data of variable quality and quantity. BPC’s automated analytical instruments consistently generate a large quantity of high-quality biotech results.
Individual skills can lead to variability in biotech analysis results. Trusting BPC’s automated instruments reduces skill-related variability, ensuring consistent and accurate results.
We will work hard to keep our intelligent analytical instruments as the top choice of universities, research institutes, and service providers worldwide.
BPC Instruments, a niche player in the biotech analytical instrument sector, operates within various larger markets, including biogas, biodegradability, animal nutrition, bioethanol, wastewater treatment, and more.
As pioneers in biogas quality analysis, we see significant growth potential with new investments and policies, such as the European Commission’s REPowerEU plan, supporting biogas production. Environmental regulations and rising energy prices have rapidly accelerated the market demand for biomethane – making it a crucial renewable energy source.
Currently, we dominate the global market with a 90 percent share in feedstock quality analysis for biogas production. We’ve also expanded into other biotech areas, such as biodegradability of plastics and in-vitro feed analysis for animal farming, aiming to lead in multiple biotech markets with a strong first-mover advantage.